		Monday, 12:05 - 1:30 PM Poster Viewing AL and ATTR amyloidosis
	Abstract Poster Nummer	**Poster Title**
Abstract ID		
117	P001	Morbidity and mortality measured through “Days Alive and Out of Hospital” (DAOH) in patients with AL amyloidosis according to cardiac involvement and specific treatment.
123	P002	Selection of appropriate quality of life instrument to measure patient-reported outcomes in systemic light chain (AL) amyloidosis
124	P003	Symptom burden and quality of life in AL amyloidosis patients among recently diagnosed and long-term survivors
157	P004	Performance of a survival staging system incorporating sST2 in patients with light chain amyloidosis
165	P005	Evaluation of the Patterns Leading to Diagnosis in Patients With Amyloid Light-Chain Amyloidosis Using the Komodo Database
174	P006	Healthcare resource utilization in patients with light chain amyloidosis in Europe
205	P007	Reduction of cardiac AL amyloid deposition after complete response visualized by PiB-PET imaging
217	P008	The impact of longitudinal strain (LS) response in patients with advanced cardiac AL amyloidosis
224	P009	CMR with T1 mapping in systemic light-chain (AL) amyloidosis: from cardiac amyloid regression to refining treatment response
231	P010	Outcomes for patients with systemic light chain (AL) amyloidosis and Mayo stage 3B disease
248	P011	Finding a needle in a haystack: oligomer detection via urinary extracellular vesicles in AL light chain amyloidosis
265	P012	Longitudinal testing for measurable residual disease (MRD) using multiparametric flow cytometry in patients with systemic light chain amyloidosis
266	P013	Racial differences in the cytogenetic underpinnings of light chain amyloidosis
277	P014	Evaluation of NT-proBNP as surrogate endpoint in AL amyloidosis: development of a platform for federated, multi-institution meta-analysis of randomized trials
280	P015	Patterns of target organ amyloid deposition in patients with AL amyloidosis; role for diagnosis and prognosis
284	P016	Diagnostic Hospitalization and Associated Costs in Patients with Amyloid Light-Chain Amyloidosis
292	P017	Atypical neurological presentation of immunoglobulin light-chain amyloidosis
297	P018	Characterization and outcome of patients with systemic AL amyloidosis requiring dialysis prior to initial therapy
325	P019	Beta-2-microglobulin and lactate dehydrogenase as prognostic parameters in light-chain amyloidosis
335	P020	Diagnostic value of liver stiffness as marker of hepatic amyloid deposition in systemic AL amyloidosis
338	P021	The Pattern of Organ Responses Varies in Patients with Systemic Light-chain Amyloidosis (AL) and Heart or Kidney or Heart and Kidney Involvement Who Achieve Deep Hematologic Responses
340	P022	Outcomes of patients with AL amyloidosis and end-stage renal disease requiring dialysis
350	P023	Identifying symptoms of AL amyloidosis in electronic health records using natural language processing, ICD codes, and manually abstracted registry data
378	P024	A revised renal staging system for long-term renal survival in patients with AL amyloidosis with renal involvement
415	P025	Role of subcutaneous abdominal fat tissue aspiration in the diagnosis of systemic immunoglobulin light-chain amyloidosis
468	P026	Functional Status and Heart Failure Quality of Life Provide Incremental Prognostic Value in Light Chain Amyloidosis
126	P027	Heart and autologous stem cells transplantation in AL amyloidosis.
134	P028	Droxidopa for Treatment of Refractory Orthostatic Hypotension in Patients with AL Amyloidosis: A Case Series
154	P029	AL Amyloidosis – a reason to transplant MGUS phenotype?
171	P030	Daratumumab for the treatment of Relapsed/Refractory AL amyloidosis: Experience from the Amyloidosis Program of Calgary (APC)
176	P031	Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3b light chain amyloidosis: a phase 2 study by the European Myeloma Network
183	P032	Role of Doxycycline in the treatment of patients with AL amyloidosis receiving Bortezomib-containing regimens in the frontline setting: Experience from the Amyloidosis Program of Calgary
185	P033	Effect of the presence of t(11;14) for patients with AL amyloidosis treated with Bortezomib-containing regimens: Experiences from the Amyloidosis Program of Calgary
186	P034	Cyclophosphamide, Bortezomib and Methylprednisolone for the treatment of AL amyloidosis: Updated report from the Amyloid Program of Calgary (APC)
200	P035	Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a phase II study
212	P036	Treatment outcomes according to salvage chemotherapy modalities for relapsed/refractory AL amyloidosis
279	P037	Autologous stem cell transplantation in primary amyloidosis: a single centre experience
294	P038	Bortezomib-based induction therapy is associated with superior hematologic responses and survival after stem cell transplantation in patients with AL amyloidosis
333	P039	Venetoclax in Relapsed or Refractory AL Amyloidosis with t(11;14) and BCL2 overexpression.
336	P040	Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory AFFIRM-AL Phase 3 Study
339	P041	Assessing clinical outcomes in patients with AL amyloidosis across different criteria for hematologic complete response: Results from ANDROMEDA
363	P042	Efficacy of bortezomib based regimens in elderly patients with newly diagnosed AL amyloidosis and heart failure.
408	P043	Time to next treatment (TtNT) is an independent prognostic marker for outcome in newly diagnosed patients with AL amyloidosis
414	P044	Second autologous stem cell transplantation as salvage therapy in selected patients with relapsed/progressed light-chain (AL) amyloidosis
418	P045	IsAMYP: a phase 2 single-stage study to evaluate the efficacy of isatuximab, pomalidomide and dexamethasone, in patients with AL amyloidosis not in VGPR or better after any previous therapy.
419	P046	Epidemiology of light-chain amyloidosis in Latin America: a retrospective analysis of 212 patients. Grupo Latinoamericano de Estudio del Mieloma Múltiple (GELAMM)
423	P047	Timeline change of AL amyloidosis treatment response and clinical outcomes; a single-center experience from Turkey
429	P048	Autologous Stem Cell Transplantation in AL amyloidosis in two centers from Latin America
431	P049	Real-world data on safety and efficacy of upfront daratumumab-based therapy in patients with light chain (AL) amyloidosis and high plasma cell burden evaluated at 3 months
433	P050	Comparison of bortesomib-based induction regimens with other treatment modalities in patients with newly diagnosed systemic light chain amyloidosis.
442	P051	Autologous stem cell transplantation (ASCT) remains effective therapy for systemic immunoglobulin light chain amyloidosis (AL): Experience from a single Australian Amyloidosis Service
471	P052	Daratumumab, pomalidomide and dexamethasone (DPd) in relapsed/refractory light chain amyloidosis previously exposed to daratumumab (NCT04270175): Interim results
475	P053	Functional Status and Heart Failure Quality of Life Improve Following Therapy in Light Chain Amyloid Cardiomyopathy
110	P054	Atrial Fibrillation Does Not Influence the Occurrence of Cerebrovascular Accidents Among Patients with Amyloidosis
116	P055	Morbidity and mortality measured through “Days Alive and Out of Hospital”(DAOH) in patients with amyloidosis.
118	P056	Factors associated with morbidity and mortality, measured through “Days Alive and Out of Hospital”(DAOH) in patients with AL and ATTR amyloidosis.
119	P057	Significant tricuspid regurgitation is associated with adverse outcomes in patients with transthyretin amyloidosis.
120	P058	Prevalence of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy
121	P059	1 Clinical findings and comorbidities in wtATTR patients with suspected amyloid neuropathy
127	P060	Identification of wild-type transthyretin cardiac amyloidosis in patients with recent CTS surgery
128	P061	Evolution of demographics of patients with transthyretin amyloid cardiomyopathy over time: implications for disease awareness strategies and future trial design
129	P062	Descriptive analysis of women with transthyretin amyloid cardiomyopathy: examining the patient demographics of a growing patient population
130	P063	Assessment and Management of Older Patients with Transthyretin Amyloidosis Cardiomyopathy: Geriatric Cardiology, Frailty Assessment and Beyond
137	P064	Preservation of Left Ventricle Stroke Volume in Patients with ATTRwt Cardiac Amyloidosis Treated with Selective TTR Stabiliser Tafamidis
143	P065	Implementation of a machine learning model to assess transthyretin amyloid cardiomyopathy risk in an external platform
156	P066	Clinical and Socioeconomic Differences Among Patients with Transthyretin Cardiac Amyloidosis Belonging to North and South of Chicago.
177	P067	Relationship of tafamidis binding site occupancy, transthyretin stabilization, and disease modification in tafamidis treated transthyretin amyloid cardiomyopathy patients
201	P068	Diagnostic Path, Clinical Characteristics and Outcomes of Patients With ATTR Cardiomyopathy in Greece
206	P069	Screening for transthyretin-related amyloidosis in patients with aortic stenosis undergoing aortic valve replacement
257	P070	Case series of the treatment journeys of patients who underwent heart transplantation for transthyretin (ATTR) cardiac amyloidosis, with subsequent confirmed orthopedic disease
275	P071	Factors Associated with Financial Toxicity in Patients with ATTR: Results From Amyloidosis Research Consortium’s ATTR Treatment Affordability Patient and Caregiver Survey
300	P072	Characterisation of Austrian Transthyretin Amyloid Cardiomyopathy (ATTR-CM) patients enrolled in a Tafamidis (61mg) early access program
311	P073	Incidence and Risk Factors for Pacemaker Implantation in Light Chain and Transthyretin Cardiac Amyloidosis
312	P074	The relationship between NT-proBNP and perception of the severity of cardiac symptoms in TTR-CA: the moderating role of anxious and depressive symptoms
316	P075	Neurological symptoms of patients with transthyretin amyloidosis at first neurological presentation at the Amyloidosis Center of Lower Saxony
346	P076	Incidence and factors associated with de novo atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosis
351	P077	Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Inotersen
355	P078	Prospective evaluation of an applied wt-ATTR-CM machine learning model to a United States (U.S.) health system electronic health record
367	P079	Prognostic Value of Cardiopulmonary Exercise Testing in Patients with Transthyretin Cardiac Amyloidosis.
381	P080	Tafamidis 61 mg for treatment of ATTR cardiomyopathy in daily clinical practice: an observational study
386	P081	Transthyretin Cardiac Amyloidosis (ATTR-CA) and its rising awareness: Patient characteristics and survival in the Australian context
389	P082	Significant survival benefits with Diflunisal in patients with Transthyretin (TTR) Amyloidosis Cardiomyopathy (ATTR-CM); A retrospective analysis
398	P083	Effect of inotersen on global longitudinal strain in transthyretin cardiac amyloidosis
402	P084	Inotersen treatment in transthyretin amyloid cardiomyopathy results in early and sustained serum transthyretin knockdown
405	P085	Baseline ECG characteristics in ATTR-CM
104	P086	REAL-WORLD EXPERIENCE WITH TAFAMIS AT CEPARM UNIVERSITY HOSPITAL. FEDERAL UNIVERSITY OF RIO DE JANEIRO. BRAZIL.
105	P087	REAL-WORLD EXPERIENCE WITH INOTERSEN AT CEPARM. UNIVERSITY HOSPITAL FEDERAL UNIVERSITY OF RIO DE JANEIRO. BRAZIL.
125	P088	Neurofilament Light Chain as a Biomarker in Hereditary Transthyretin-Mediated Amyloidosis: 36-Month Data from the Patisiran Global Open-Label Extension
139	P089	Characteristics of patients with ATTR amyloidosis and the Ile107Val mutation: insights from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
141	P090	Analysis of cardiac involvement in hereditary transthyretin amyloidosis after liver transplantation
144	P091	4 Effect of Patisiran on Polyneuropathy and Cardiomyopathy in Patients with hATTR Amyloidosis with V122I/T60A Variants: A Phase 4 Observational Study
152	P092	Transthyretin amyloid polyneuropathy in mainland China: a unicentric study
162	P093	Phenotype and Clinical Outcomes of Hereditary Transthyretin Amyloidosis caused by p.Glu109Lys TTR Variant. A new endemic variant in Spain
163	P094	Comparison of disability: intradermal vasomotor nerves, intradermal sudomotor nerves, and intraepidermal sensory nerves in hereditary transthyretin amyloidosis
168	P095	A descriptive analysis of patients with ATTR amyloidosis and a mixed phenotype from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
188	P096	Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study.
199	P097	Characterization of patients with hereditary Transthyretin Amyloidosis in a Register Study in Germany
209	P098	Hereditary Transthyretin Amyloidosis (ATTRv) in the Middle East: a short report of two confirmed cases
216	P099	How occupational needs can be obtained? A Semi-Structured Interview with Hereditary Transthyretin Amyloidosis patients.
218	P100	A rare case of late-onset hereditary ATTR Amyloidosis with cardiac and neurologic manifestation
235	P101	5 Characteristics of patients with ATTR amyloidosis and the Ser77Tyr mutation: insights from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
252	P102	EFFECTIVENESS OF PATISIRAN FOLLOWING SWITCH FROM TAFAMIDIS FOR THE TREATMENT OF HEREDITARY TRANSTHYRETIN-MEDIATED (hATTR) AMYLOIDOSIS WITH POLYNEUROPATHY
234	P103	Characteristics of patients with ATTR amyloidosis and the Ile68Leu mutation: insights from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
258	P104	8 Characteristics of Patients With ATTR Amyloidosis and the Phe64Leu Mutation: Insights From the Transthyretin Amyloidosis Outcomes Survey (THAOS)
281	P105	Effect of tafamidis on disease progression in patients with non-Val30Met transthyretin amyloid polyneuropathy: a sub-study of the Transthyretin Amyloidosis Outcomes Survey (THAOS)
304	P106	Cardiological evolution of hereditary transthyretin amyloidosis (AhTTR) in patients with liver transplant
313	P107	Hereditary Transthyretin Amyloidosis caused by p.Ser43Asn TTR Variant. Insights and possible founder effect in Ecuador.
334	P108	A-V block as presentation of cardiac amyloid caused by conduction tissue infiltration
356	P109	Comparing patient and clinician perspectives of ATTR amyloidosis: Insights from the development of the Transthyretin Amyloidosis Quality of Life (ATTR-QOL) Questionnaire
372	P110	Peritoneal dialysis is a valid treatment option in hereditary transthyretin amyloidosis
388	P111	Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP): Electroneuromyographic findings in eighteen newly diagnosed patients
404	P112	Case series: p.Leu131Met transthyretin amyloidosis in a Danish family: Pure cardiac phenotype?
413	P113	20 years of symptomatic and presymptomatic genetic testing for hereditary transthyretin amyloidosis (ATTR) in the Balearic Islands
416	P114	Cardiac Screening of Amyloid TTR Pathogenic Variant Carriers: Complementary value of Echocardiographic Global Longitudinal Strain Imaging versus Bone scintigraphy
421	P115	Comparison of Amyloid Detection in the Skin and Tenosynovium of Transthyretin Amyloidosis Patients
438	P116	A rare TTR mutation determining severe cardiac and neurological amyloidosis
449	P117	Lung volume restriction and abnormal cardiopulmonary response to exercise: red warning lights in transthyretin cardiac amyloidosis
456	P118	Evaluation and follow-up of the sudomotor function in a cohort of ATTRv patients from a non-endemic area
457	P119	The Relation between African American Race, Genotype, and Prognosis in Transthyretin Cardiac Amyloidosis

466	P120	Pre-symptomatic genetic testing for hereditary transthyretin amyloidosis: a 20-year single-centre experience
480	P121	Peripheral nerve and cardiac features in hATTR patients presenting with active disease V122I, L58H and late-onset V30M in the US
298	P208	Prospective MALDI-TOF analysis of blood serum peptidome to predict the onset and progression of hereditary transthyretin amyloidosis.
		Tuesday 12:05 - 1:15 PM Poster viewing
173	P122	Amyloid fibril formation is suppressed by UV irradiation
181	P123	An additive destabilizing effect of two substitutions, T60I/V122I, in heterozygous compound TTRv amyloidosis
189	P124	Selective recognition of human small transthyretin aggregates by a novel monoclonal antibody
198	P125	Domain-domain interactions and dimerization of the human λ-III immunoglobulin light chain FOR005 investigated by NMR spectroscopy
239	P126	ALBase: an updated platform to study immunoglobulin light chain sequences
293	P127	Structure-based peptides as novel therapeutic and detection tools in cardiac amyloidosis
318	P128	Alternative pathogenic mechanisms and novel pharmacological approaches in gelsolin amyloidosis
368	P129	Coagulative and fibrinolytic blood proteases efficiently cleave human transthyretin (hTTR) oligomers in vitro to generate the amyloidogenic fragment hTTR(49-127)
370	P130	Mechanism of Misfolding and Amyloid Aggregation of the λ6 Light Chains
371	P131	Filling the gap for transthyretin amyloidosis: biochemical and structural studies of in vitro and in vivo assembled amyloid fibrils
385	P132	Modulation of transthyretin aggregation: role of preformed fibrils and heparin
392	P133	Circulating forms of plasma transthyretin in patients with wild-type transthyretin amyloidosis and effects of tafamidis
409	P134	Early Events of Immunoglobulin Light Chain Aggregation: Role of the C-terminus Disulfide Bond
434	P135	Recommendations for Addressing the Translational Gap between Experimental and Clinical Research on Amyloid Diseases
437	P136	Proteolytic stability of amyloid isolated from human cataract eye lens
448	P137	Clusterin in Alzheimer's disease: friend or foe?
454	P138	Study of berry distinct polymorphism in ATTR amyloidosis fibrils by cryo-EM
161	P139	Cardiac proteotoxicity is resulting from a complex interplay of several molecular properties of amyloidogenic Light Chains
210	P140	Assessing Immunoglobulin Light Chain Protein Stability and Stabilization by Pharmacological Chaperones Using Differential Scanning Fluorimetry
221	P141	Limited cardiomyocytes' growth response to stimulation with human plasma and phenylephrine predicts poor outcome in ATTR cardiomyopathy in an in-vitro model.
286	P142	When Amyloid Occupies the Bone Marrow: Are the Responses of CD138-depleted Cells from Marrows with Interstitial Amyloid Archetypal?
321	P143	Exploring the in vitro effects of light chain-induced proteotoxicity on primary human cardiovascular system cells
396	P144	Exploring Alzheimer's disease (AD) related human brain proteome with MALDI Imaging Mass Spectrometry in combination with shotgun proteomics
455	P145	Transthyretin (hTTR) Amyloid Fibrils Trigger Plasma Clotting by Activating the Intrinsic Pathway of Blood Coagulation: Implications in Cardiac Senile Systemic Amyloidosis
470	P146	
178	P147	V30M TTR animal model displayed a downregulated expression of several chemokines in different immune cell populations
180	P148	In vitro treatment of light-chain amyloidosis plasma cells to characterize response to venetoclax
222	P149	Frequent Occurrence of Fibrinogen Amyloidosis in Japanese Squirrels (Sciurus lis)
267	P150	Exercise suppresses mouse systemic AApoAII amyloidosis through enhancement of the p38 MAPK signaling pathway
270	P151	Characterization of heterozygous ATTR Y114C amyloidosis-specific iPS cells
285	P152	BiP deletion leads to decreased cell viability and antibody production in multiple myeloma cell lines
315	P153	Age-related amyloid deposition in C57BL/6 mice: Pathological findings and characterization of the renal damage
326	P154	HEMOSTASIS DYSFUNCTION INDUCES SENILE APOA2 AMYLOIDOSIS IN A MOUSE MODEL
331	P155	Endocytic inhibitory drugs protect C. elegans from the toxicity of amyloidogenic light chains
337	P156	Is C. elegans a good model of β2-microglobulin related amyloidosis?
345	P157	Expression hosts matter: Differences between immunoglobulin light chain (AL) full length proteins expressed in bacteria and human cells
361	P158	Efficient transient expression of exogenous immunoglobulin light chain (AL) full length proteins from cultured human cells
395	P159	Strategies to induce amyloid light chain deposition in a transgenic mouse model
115	P160	Prognostic Implication of Longitudinal Changes of Left Ventricular Global Strain after Chemotherapy in Cardiac Light Chain Amyloidosis
158	P161	Amyloid Valvular Heart Disease: A Look Beyond the Ventricular Walls
169	P162	Scintigraphy Scan with planar and SPECT imaging of the chest using Technetium 99m Pyrophosphate for the assessment of AL Amyloidosis: Comparison with an ATTR cohort of patients
196	P163	A kit method for direct radiolabeling the amyloid reactive peptide p5+14 with technetium-99m (99mTc) for the detection of cardiac amyloidosis by SPECT/CT imaging
197	P164	Quantitative changes in organ-specific amyloid load in a patient with AL amyloidosis, measured by 124I-AT-01 PET/CT imaging, correlate with serum biomarkers
208	P165	The role of speckle tracking echocardiography in the diagnostic assessment of cardiac amyloidosis and Fabry disease
223	P166	Assessment of Incidental Cardiac Uptake in Bone Scintigraphy across Spain. ECCINGO Study
230	P167	Valve disease in cardiac amyloidosis: an echocardiographic score
233	P168	Coronary flow reserve by PET 13N-Ammonia in patients with Hereditary Transthyretin Amyloidosis with and without cardiac involvement.
240	P169	Differentiation of ATTR amyloidosis based on abdominothoracic organ-specific uptake of 124I-AT-01 (124I-p5+14) assessed by PET/CT imaging
241	P170	Detection of extracardiac amyloid in patients with ATTR amyloidosis by PET/CT imaging using the amyloidophilic radiotracer 124I-AT-01 (124I-p5+14)
242	P171	Myocardial stiffness evaluation using atrial kick in healthy controls and patients with cardiac amyloidosis: a pilot study
245	P172	[99mTc]Tc-DPD Scintigraphy Associating Semi-Quantitative Methods for the Diagnosis of Cardiac Amyloidosis: Experience in an Endemic Area
255	P173	Myocardial Contraction Fraction (MCF): A Simple Measure of Myocardial Shortening That is Associated with Longitudinal and Circumferential Strain in Transthyretin Cardiac Amyloidosis.
290	P174	90 Histological validation of cardiac 99mTc-DPD uptake in patients with cardiac transthyretin amyloidosis
291	P175	Is a change of the current echocardiographic red flag for left ventricular wall thickness useful in cardiac amyloidosis screening?
299	P176	Prognosis of light chain amyloidosis with biopsy-proven cardiac involvement
302	P177	Multi-imaging characterisation of cardiac phenotype in different types of amyloidosis
310	P178	Prognostic Implications of Clinical Phenotype and Severity of Cardiac Involvement in Patients Presenting with Immunoglobulin Light Chain Amyloidosis
344	P179	Diagnostic performance characteristics of quantitative and semi-quantitative parameters of Tc99m pyrophosphate imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: The SCAN-MP Study
377	P180	DPD scintigraphy – a biomarker of microcalcifications rather than amyloid
383	P181	Prognostic Role of Echocardiographic Right Ventricular Parameters in Patients with Wild-Type ATTR Cardiac Amyloidosis
390	P182	False positive bone-scintigraphy in elderly hypertrophic cardiomyopathy
399	P183	Dual-echo turbo-spin-echo and 12-echo multi-spin-echo sequences are equivalent techniques for obtaining T2-Relaxometry data in hereditary transthyretin amyloidosis
412	P184	CARDIAC IMAGING FOR ASSESSING INVOLVEMENT IN AL AMYLOIDOSIS PATIENTS: EXPERIENCE IN A SINGLE TERTIARY HOSPITAL
422	P185	Phenotyping of hypertrophic cardiomyopathies using echocardiography: amyloid, Anderson-Fabry and hypertensive heart disease
461	P186	Multimodality cardiac imaging in differential diagnosis of infiltrative cardiomyopathy
465	P187	Quantification of left ventricular amyloid using 124I-p5+14 (AT-01) and 18F-florbetapir positron emission tomography in AL and ATTR amyloidosis
467	P188	Changes in Left Ventricular Myocardial Composition Following Targeted Plasma Cell Therapy in Light Chain Amyloidosis: A Cardiac Magnetic Resonance Study
469	P189	Evaluation of Echocardiographic Parameters for Prognostication in Patients with Systemic Light Chain Amyloidosis
473	P190	Central Nervous System damage in hereditary Transthyretin Amyloidosis: A multimodal MRI study
		Tuesday 7:00 - 7:30 PM; Poster Viewing
490	PLB001	Amyloid Multidisciplinary Hybrid Clinic: A novel model of care in the age of telehealth
489	PLB002	Burden of transthyretin amyloid cardiomyopathy in patients and caregivers: interim analysis of a large, ongoing, non-interventional study
484	PLB003	Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018
502	PLB004	Ixazomib maintenance following initial therapy in patients with high-risk immunoglobulin light chain (AL) amyloidosis.
481	PLB005	Macroglossia, a Sign of A.L. Amyloidosis in a Case of Recurrent Pleural Effusion
503	PLB006	Mid-term analysis of the Clinical Amyloidosis Registry in Germany
487	PLB007	On bead de-glycosylation coupled with MALDI-TOF mass spectrometry provides a simple method for confirming light chain glycosylation and provides a sensitive method for residual disease detection
492	PLB008	Real World Patient, Advocate, and Caregiver Perspectives on Amyloidosis: Awareness, Knowledge Gaps, and Psychosocial Impact
485	PLB009	Renal histopathological scoring of amyloid deposits is crucial to assess disease progression in light-chain (AL) amyloidosis: a multicentre retrospective study
498	PLB010	
499	PLB011	Retrospective Cohort Study of treatment with BCL-2 inhibitor Venetoclax in relapsed or refractory AL amyloidosis
494	PLB012	Tafamidis medication adherence in patients with transthyretin cardiac amyloidosis (ATTR-CM) in a Japanese medical claims database
500	PLB013	The impact of renal histopathology on the renal outcome for newly diagnosed patients with AL amyloidosis
493	PLB014	The patient voice: development and results of a pilot patient experience data (PED) survey
497	PLB015	The role of local complement expression in renal amyloidogenic light chain amyloidosis
496	PLB016	Transthyretin tetramer destabilization, marked by lower plasma transthyretin, is causally associated with increased risk of all-cause and cardiovascular mortality in the general population
495	PLB017	Two-year follow-up of the first case of systemic light chain amyloidosis treated with anti-B cell maturation antigen -CAR T cells
		Wednesday 12:05 - 1:20 PM; Poster Viewing
109	P191	Quantitative Sensory Testing: a good tool to differentiate between an asymptomatic carrier from an early symptomatic ATTRv amyloidosis patient?
132	P192	The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease
138	P193	Manifestations of chronic heart failure in patients with AL-amyloidosis and ATTR-amyloidosis. Prospective observation data.
146	P194	Artificial Intelligence Enhanced Electrocardiogram: A Simple Tool to Monitor for Clinical Improvement in Cardiac Amyloidosis?
147	P195	Diagnostic and therapeutic center for amyloidosis at Kumamoto University
150	P196	EXPERIENCES AND DECISION-MAKING IN CONFIRMED AND POTENTIAL CARRIERS OF ATTR-RELATED GENETIC VARIANTS
153	P197	Potential sources of error in the identification and referral of amyloidosis to a tertiary center
166	P198	Higher Length of Stay and Readmission Burden in Heart Failure Patients with Cardiac Amyloidosis Than Those without
207	P199	MANAGEMENT AND PATIENT ESTIMATION OF AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS IN PORTUGAL: RESULTS FROM A PHYSICIANS' SURVEY
228	P200	Prevalence of pauci-symptomatic amyloid transthyretin cardiac amyloidosis in the general population
229	P201	Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies
238	P202	Finding a balance between specialist and local care: amyloidosis patient perspectives on a single-centre approach
243	P203	Multidisciplinary approach for the early detection of amyloid in patients who undergo carpal tunnel syndrome or lumbar stenosis surgery. Preliminary results of an ongoing study.
250	P204	Artificial Intelligence-Enhanced Models To Predict Light Chain Amyloidosis From Patients With Monoclonal Gammopathy Of Undetermined Significance And Smoldering Multiple Myeloma
251	P205	Lumbar spinal stenosis syndrome as surrogate for transthyretin cardiac amyloidosis
254	P206	Expert recommendations for improving the implementation of nuclear scintigraphy to support accurate diagnosis of cardiac amyloidosis in a non-specialist setting
295	P207	Amyloidosis and its multifaces: A case report
	P208	see Monday
322	P209	Real-life evaluation of an algorithm for the diagnosis of cardiac amyloidosis
341	P210	Optimal Patient Selection for Referral to Tc-99m-PYP Scanning for Transthyretin Cardiac Amyloidosis
342	P211	Cardiac amyloidosis screening in a cohort of patients with spinal stenosis: a case series.

349	P212	Changes in the Journey to Diagnosis of Cardiac Amyloidosis in the Past 10 Years: Results from the Amyloidosis Research Consortium's 2017 Cardiac Survey and 2022 Amyloidosis Community Survey
365	P213	Prognostic Value of an Artificial Intelligence Enhanced ECG Model in Cardiac Amyloidosis
379	P214	Retrospective analysis of a patient cohort with suspicion of systemic amyloidosis, finally not confirmed
380	P215	Validation of Amylo-AFFECT, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis
382	P216	The landscape of amyloidosis in Switzerland: Report of the Amyloidosis Registry
384	P217	Low QRS voltages in cardiac amyloidosis: echocardiographic correlates and prognostic value
403	P218	Clinical impact of musculoskeletal pathology in patients with transthyretin-associated amyloidosis (ATTR): retrospective analysis of the case series from our center
406	P219	EARLY DETECTION OF HEREDITARY AMYLOIDOSIS
420	P220	ROLE OF COMBINING AI-ECG TO CLINICAL RISK SCORES FOR THE PREDICTION OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION
427	P221	Prevalence and Implications of Classic ECG Findings in a Contemporary ATTR Cohort
432	P222	Prevalence of Daytime and Nighttime Central Apneas in Patients with Cardiac Amyloidosis
436	P223	The distribution of amyloidosis diseases in Germany: National Clinical Amyloidosis Registry
441	P224	Amyloidosis diagnoses and shifting distribution of ATTR and AL from 2019 to 2021: a German single center experience.
444	P225	Initial Experience of a Private Amyloidosis Center
458	P226	From symptoms and signs to diagnosis – Development of a simple screening tool for hereditary transthyretin amyloidosis (AmyloScan©)
463	P227	Determining amyloid subtype: a retrospective comparative study between a clinical, laboratory, imaging, and pathological model and mass spectrometry
464	P228	Cardiac amyloidosis in Latin America: Opportunities to increase disease awareness among clinicians. Findings from the AMILO-LATAM research group
477	P229	Quality assessment of teaching in transthyretin amyloidosis
111	P230	Glomerular and tubular renal function in patients with Hereditary Transthyretin Amyloidosis (ATTR)
135	P231	Targeted sequencing of functionally selected genes in patients with wild-type transthyretin amyloidosis
215	P232	Detection of amyloidogenic FLC in serum as a non-invasive tool to facilitate the diagnosis of AL amyloidosis
226	P233	Immunoglobulin high-throughput sequencing in Monoclonal Gammopathy of Clinical Significance (MGCS): experience of the French Amyloidosis center
269	P234	Neurofilament light chain, an early biomarker for polyneuropathy in hereditary transthyretin-related (ATTRv) amyloidosis
283	P235	The Clusterin/von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-type Than from λ-isotype Monoclonal Gammopathy Patients
308	P236	A spectrum of clinical phenotypes associated with p.(Arg54Gly) TTR variant.
323	P237	Neurofilament light chain as early biomarker for hereditary transthyretin amyloidosis – the Swedish experience
400	P238	Neurofilament light chain measurement in hereditary transthyretin-related amyloidosis patients with myocardial sympathetic neuronal damage: substitution for 123I-meta-iodobenzylguanidine scintigraphy?
443	P239	Prevalence of variant genotype in patients with suspected cardiac ATTR amyloidosis
450	P240	Engraftment Syndrome After ASCT is Associated elevated IL-10 and IP-10 (CXCL10) levels
476	P241	Genetic modifiers in hereditary and acquired TTR amyloidosis: a genome-wide association study
122	P242	Skin Biopsy Has A High Diagnostic Yield In Patients With Systemic Amyloidosis And Neuropathy.
179	P243	Assessing amyloid prevalence, type, and extent of burden in the ligamentum flavum of patients with spinal stenosis undergoing routine laminectomy
191	P244	Prevalence of Localized Amyloid in Ligamentum Flavum of Patients with Lumbar Spinal Stenosis
203	P245	Definition of Bone marrow biopsy involvement in amyloidosis – proposal for reporting
214	P246	Detection of amyloid deposits in skin biopsies of patients with clinically suspected variant transthyretin amyloidosis
227	P247	Amyloid deposits are common in different spinal structures among patients with spinal stenosis referred for decompression surgery
236	P248	Diagnosis and typing of pulmonary amyloidosis: A series of cases
253	P249	Concurrent light chain amyloidosis and proximal tubulopathy: insights into different aggregation behavior.
268	P250	Clinicopathological analyses of an autopsied case with hereditary ATTR amyloidosis 22 years after liver transplantation
288	P251	Clinical ApoA-IV amyloid is associated with fibrillogenic signal sequence
303	P252	Removal of Cardiac AL-Amyloid leads to Cardiomyocyte Positive Remodeling and Restrictive Pattern Reversal
309	P253	Degree of transthyretin fragmentation in ATTR amyloidosis tissues
314	P254	Glomerular proteomics – unmasking sub-clinical amyloid or false positive?
332	P255	Complement in amyloidosis – immunohistochemical verification of activation of the complement system in renal light-chain amyloidosis
357	P256	Trends in renal amyloidosis over a 30-year period: Data from the Norwegian Kidney Biopsy Registry 1988 – 2017
358	P257	Clinical and Morphological Phenotypes of AL and ATTR Amyloidosis Detected via Gastrointestinal Biopsies
366	P258	Amyloid deposition in granuloma of tuberculosis patients: A single-center pilot study
375	P259	The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 332 patients
425	P260	MANAGING PATIENTS WITH CARPAL TUNNEL SYNDROME AND POSITIVE CONGO RED STAIN: A WORK IN PROGRESS
435	P261	RNA-sequencing reveals similarity of AL amyloidosis and MGUS aberrant cells along with several potential target genes
445	P262	Presentation and outcome of patients with coexisting cardiac AL and ATTR amyloidosis
451	P263	Validation of a mouse anti-human Serum Amyloid A antibody immunohistological test for diagnostic clinical practice.
453	P264	Patients with two different systemic amyloidoses – a case series
148	P265	The use of abdominal fat aspiration biopsy to quantify the amyloid burden during long-term follow-up of patients with AA amyloidosis
274	P266	Renal amyloidosis in people who inject drugs in Oslo, Norway.
287	P267	Properties of generic monoclonal AA antibodies for classifying most vertebrate AA amyloidoses, and as probes for innate functions of SAA
301	P268	SARS-Cov2 infection in AA amyloidosis: a high rate of mortality
164	P269	Clinicopathological characteristics of a Japanese case with fibrinogen Aα-chain amyloidosis
194	P270	Hereditary Gelsolin amyloidosis: Clinical features from a large cohort in the US
204	P271	Siblings with a novel type of amyloid neuropathy, hereditary Aβ2M amyloid neuropathy: Report of the second family in the world
211	P272	Apolipoprotein A-IV amyloidosis in a Cotton-top tamarin (Saguinus oedipus)
213	P273	Histological and proteomic analyses of semenogelin 1 amyloid deposits
225	P274	Mass spectrometry-based proteomic analysis of adsorbed molecules related with dialysis-related amyloidosis in hexadecyl-immobilized cellulose beads.
369	P275	Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 mutation
394	P276	Iatrogenic cerebral amyloid angiopathy
474	P277	Fibrinogen A alpha-chain amyloidosis journey: dialysis and kidney transplantation interface
131	P278	NNC6019-0001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial
151	P279	Efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: a phase 2 study by the European Myeloma Network
172	P280	Glavonoid, a possible prophylactic supplement for ATTR amyloidosis
237	P281	Safety and tolerability of CAEL-101, an anti-amyloid monoclonal antibody, combined with anti–plasma cell dyscrasia therapy in patients with light-chain (AL) amyloidosis: results from a phase 2 study
246	P282	Preclinical characterization of AT-04, a pan-amyloid-binding Fc domain-peptide fusion, to serve as an opsonin for macrophage-mediated clearance of amyloid deposits
256	P283	Characteristics of patients with hereditary transthyretin amyloidosis-polyneuropathy (ATTRv-PN) in NEURO-TTRansform, a phase 3 study of eplontersen
263	P284	AT-03 Demonstrated Pan-amyloid Binding and Stimulated the Removal of Amyloid Deposits through Macrophage-Mediated Phagocytosis
296	P285	Design and Evaluation of shRNA Polyplex with Cyclodextrin-modified Dendrimer for Treatment of Systemic and Localized Amyloidosis
307	P286	Rational design of AML therapeutic agents that specifically bind and clear diverse amyloid aggregates
328	P287	DEVELOPMENT OF NEW ANTIBODY-BASED THERAPIES AGAINST SYSTEMIC AMYLOIDOSES
329	P288	Exploring the inhibitory effect of a natural product, Siderol, on the aggregation of Amyloid-β peptide.
354	P289	A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis
359	P290	Venetoclax and simvastatin synergize to enhance responses in AL amyloidosis harboring t(11;14)
407	P291	Exploiting existing drugs against Alzheimer's disease: a protein-drug interaction network approach
410	P292	Inhibition of antibody light chain amyloid formation by small molecules
424	P293	Cell-Penetrating Peptides with Unexpected Anti-Amyloid Properties
426	P294	Discovering Potent Small Molecule Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains
478	P295	Long Term Survival of AL Patients Treated on Phase 1 trial of CAEL-101